FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo, Lannett Deal

Proposed FTC order requires divestiture of four drug products to resolve anticompetitive concerns The Federal Trade Commission took action to protect American patients from higher drug costs by requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc. View Press Release